US Biosimilar Pathway Unlikely to be Used†: Developers Will Opt for a Traditional BLA Filing

ISSN： 1173-8804

Source： BioDrugs, Vol.25, Iss.1, 2011-02, pp. : 63-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

By Genazzani Armando A.

BioDrugs, Vol. 21, Iss. 6, 2007-01 ,pp. : 351-356

Adis International

Access to resources Recommend Favorite

The US Approach to Biosimilars: The Long-Awaited FDA Approval Pathway

By Calvo Begoña Zuñiga Leyre

BioDrugs, Vol. 26, Iss. 6, 2012-12 ,pp. : 357-361

Adis International

Access to resources Recommend Favorite

Physicochemical and Biologic Comparability of a Biosimilar Granulocyte Colony-Stimulating Factor with Its Reference Product

By Sörgel Fritz Lerch Helmut Lauber Thomas

BioDrugs, Vol. 24, Iss. 6, 2010-12 ,pp. : 347-357

Adis International

Access to resources Recommend Favorite

Evaluation of Process Efficiency and Bioequivalence of Biosimilar Recombinant Human Chorionic Gonadotropin (rhCG)

By > >

BioDrugs, Vol. 25, Iss. 2, 2011-04 ,pp. : 115-127

Adis International

Access to resources Recommend Favorite

Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®): A Double-Blind, Single-Dose, Crossover Study in Healthy Volunteers

By Yi SoJeong > Park Min-Kyu > Cho Joo-Youn > Shin Sang-Goo Jang In-Jin Yu Kyung-Sang

BioDrugs, Vol. 26, Iss. 3, 2012-06 ,pp. : 177-184

Adis International

Access to resources Recommend Favorite